Coherus BioSciences (NASDAQ:CHRS - Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.04), RTT News reports. The company had revenue of $7.60 million for the quarter, compared to analyst estimates of $59.79 million. During the same quarter last year, the business posted ($0.32) EPS.
Coherus BioSciences Stock Performance
Coherus BioSciences stock traded down $0.01 during trading hours on Friday, reaching $0.76. 1,600,689 shares of the company's stock traded hands, compared to its average volume of 2,724,037. The firm has a market capitalization of $88.23 million, a price-to-earnings ratio of -9.51 and a beta of 1.01. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The firm's 50 day moving average is $0.93 and its 200-day moving average is $1.13.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on CHRS shares. StockNews.com lowered shares of Coherus BioSciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. UBS Group restated a "neutral" rating and issued a $1.05 price objective (down previously from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Coherus BioSciences in a research report on Tuesday, April 29th.
Read Our Latest Report on Coherus BioSciences
About Coherus BioSciences
(
Get Free Report)
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Featured Stories
Before you consider Coherus BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus BioSciences wasn't on the list.
While Coherus BioSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
